LOKELMA is a highly selective, innovative K+ binder that is different than other K+ binders1,2

How LOKELMA works

Watch the video to find out more about LOKELMA's mechanism of action.

LOKELMA is a modern K+ binder that preferentially captures K+ and exchanges it for hydrogen and sodium.1,2 LOKELMA has a unique crystal lattice structure.2

LOKELMA is a modern K+ binder that preferentially captures K+ and exchanges it for hydrogen and sodium.1,2

LOKELMA has a unique crystal lattice structure.2

LOKELMA is insoluble and does not expand in water, so it is not expected to swell within the GI tract.2

 

Mechanism of action table of LOKELMA
Mechanism of action table of LOKELMA

*Brand names for SPS include Kayexalate® and Kionex®.

In vitro, LOKELMA has a high affinity for K+, even in the presence of other cations such as calcium and magnesium.1

In vitro study; based on simulated intestinal fluid.2

§Based on nonclinical and early-phase studies.12

||The sodium content/unit dose of LOKELMA is 400 mg/5 g, but the extent of absorption by the patient is unknown. The recommended maintenance dose range for patients not on dialysis is 5 g qod to 15 g daily (sodium content: 400 mg qod-1200 mg daily) and for patients on dialysis is 5 g to 15 g once daily, on non-dialysis days (sodium content: 400 mg-1200 mg daily on non-dialysis days).1

The sodium content/unit dose of SPS is 1500 mg/15 g. The in vivo efficiency of sodium-potassium exchange for SPS is approximately 33%; hence, about one-third of the actual sodium content is delivered to the body.3 The recommended dose for SPS is 15 g 1 to 4 times daily.3,9,10

#Patient can add more water if desired.

 

Clinical pharmacology does not correlate with efficacy or safety.

LIMITATION OF USE: LOKELMA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.1

LOKELMA causes a small dose-dependent increase in serum bicarbonate concentrations (1.1 mEq/L at 5 g once daily, 2.3 mEq/L at 10 g once daily and 2.6 mEq/L at 15 g once daily as compared with a mean increase of 0.6 mEq/L in patients treated with placebo). The clinical significance of this finding is unclear.1

 

Veltassa is a registered trademark of Relypsa, Inc., a Vifor Pharma Group Company.

Kayexalate® was a registered trademark of Concordia Pharmaceuticals, Inc.

Kionex is a registered trademark of Paddock Laboratories, LLC.

GI=gastrointestinal; qod=every other day; SPS=sodium polystyrene sulfonate.

Review dosing information for LOKELMA